Literature DB >> 15481319

Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease.

Nirmal Kaur1, Thomas C Mahl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15481319     DOI： 10.1023/b:ddas.0000042246.58984.98

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  19 in total

1.  Reactivation of histoplasmosis after treatment with infliximab.

Authors:  Masha Nakelchik; Julie E Mangino
Journal:  Am J Med       Date:  2002-01       Impact factor: 4.965

2.  Listeria meningitis after treatment with infliximab.

Authors:  Binita M Kamath; Petar Mamula; Robert N Baldassano; Jonathan E Markowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-04       Impact factor: 2.839

Review 3.  Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab?

Authors:  Alan Shand; Alastair Forbes
Journal:  Int J Colorectal Dis       Date:  2002-08-14       Impact factor: 2.571

4.  Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy.

Authors:  Daniel Helbling; Thomas H Breitbach; Martin Krause
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 2.566

Review 5.  Infliximab treatment of sarcoidosis.

Authors:  Ryan N Serio
Journal:  Ann Pharmacother       Date:  2003-04       Impact factor: 3.154

Review 6.  Infliximab therapy in Crohn's disease: safety issues.

Authors:  D W Hommes; S J H van Deventer
Journal:  Neth J Med       Date:  2003-04       Impact factor: 1.422

7.  A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Authors:  S E Plevy; C J Landers; J Prehn; N M Carramanzana; R L Deem; D Shealy; S R Targan
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

8.  Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma.

Authors:  A G Oehling; C A Akdis; A Schapowal; K Blaser; M Schmitz; H U Simon
Journal:  Allergy       Date:  1997-02       Impact factor: 13.146

9.  Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.

Authors:  T T MacDonald; P Hutchings; M Y Choy; S Murch; A Cooke
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

Review 10.  Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Authors:  Hyon J Kwon; Timothy R Coté; Michael S Cuffe; Judith M Kramer; M Miles Braun
Journal:  Ann Intern Med       Date:  2003-05-20       Impact factor: 25.391
View more
  14 in total

Review 1.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.

Authors:  Thomas G Cotter; Nicola Gathaiya; Jelena Catania; Edward V Loftus; William J Tremaine; Larry M Baddour; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn; Andrew H Limper; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-21       Impact factor: 11.382

3.  Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.

Authors:  Michelle Wilkison; Katherine Gauss; Yanchao Ran; Steve Searles; David Taylor; Nicole Meissner
Journal:  Am J Pathol       Date:  2012-05-22       Impact factor: 4.307

4.  Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics.

Authors:  Dorota Maciejewska; Jerzy Zabinski; Pawel Kaźmierczak; Mateusz Rezler; Barbara Krassowska-Świebocka; Margaret S Collins; Melanie T Cushion
Journal:  Eur J Med Chem       Date:  2011-12-13       Impact factor: 6.514

5.  Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem?

Authors:  Omer Omer; Patrizia Cohen; Shuet Fong Neong; Geoffrey V Smith
Journal:  Frontline Gastroenterol       Date:  2014-09-22

6.  Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures.

Authors:  Melanie T Cushion; Margaret S Collins
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

7.  Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease.

Authors:  Millie D Long; Francis A Farraye; Philip N Okafor; Christopher Martin; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

8.  Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.

Authors:  Nirmal Kaur; Thomas C Mahl
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.487

9.  Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.

Authors:  Jing Wang; Francis Gigliotti; Samir P Bhagwat; Thaddeus C George; Terry W Wright
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

10.  Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease.

Authors:  Soichi Itaba; Tsutomu Iwasa; Yojiro Sadamoto; Toshifumi Nasu; Tadashi Misawa; Koji Inoue; Hidehiko Shimokawa; Kazuhiko Nakamura; Ryoichi Takayanagi
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.487
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.